Anti-HLAC/ HLA-C/ D6S204 monoclonal antibody
Anti-HLAC/ HLA-C/ D6S204 antibody for FACS & in-vivo assay
Go to HLA-C/HLA-C products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-MP0581-Ab-1/ GM-Tg-hg-MP0581-Ab-2 | Anti-Human HLA-C monoclonal antibody | Human |
GM-Tg-rg-MP0581-Ab-1/ GM-Tg-rg-MP0581-Ab-2 | Anti-Rat HLA-C monoclonal antibody | Rat |
GM-Tg-mg-MP0581-Ab-1/ GM-Tg-mg-MP0581-Ab-2 | Anti-Mouse HLA-C monoclonal antibody | Mouse |
GM-Tg-cynog-MP0581-Ab-1/ GM-Tg-cynog-MP0581-Ab-2 | Anti-Cynomolgus/ Rhesus macaque HLA-C monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-MP0581-Ab-1/ GM-Tg-felg-MP0581-Ab-2 | Anti-Feline HLA-C monoclonal antibody | Feline |
GM-Tg-cang-MP0581-Ab-1/ GM-Tg-cang-MP0581-Ab-2 | Anti-Canine HLA-C monoclonal antibody | Canine |
GM-Tg-bovg-MP0581-Ab-1/ GM-Tg-bovg-MP0581-Ab-2 | Anti-Bovine HLA-C monoclonal antibody | Bovine |
GM-Tg-equg-MP0581-Ab-1/ GM-Tg-equg-MP0581-Ab-2 | Anti-Equine HLA-C monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-MP0581-Ab-1/ GM-Tg-hg-MP0581-Ab-2; GM-Tg-rg-MP0581-Ab-1/ GM-Tg-rg-MP0581-Ab-2; GM-Tg-mg-MP0581-Ab-1/ GM-Tg-mg-MP0581-Ab-2; GM-Tg-cynog-MP0581-Ab-1/ GM-Tg-cynog-MP0581-Ab-2; GM-Tg-felg-MP0581-Ab-1/ GM-Tg-felg-MP0581-Ab-2; GM-Tg-cang-MP0581-Ab-1/ GM-Tg-cang-MP0581-Ab-2; GM-Tg-bovg-MP0581-Ab-1/ GM-Tg-bovg-MP0581-Ab-2; GM-Tg-equg-MP0581-Ab-1/ GM-Tg-equg-MP0581-Ab-2 |
Products Name | Anti-HLA-C monoclonal antibody |
Format | mab |
Target Name | HLA-C |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-HLA-C benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species HLAC/ HLA-C/ D6S204 VLP (virus-like particle) (Products Developing) |
Target information
Target ID | GM-MP0581 |
Target Name | HLA-C |
Gene ID | 3107 |
Gene Symbol and Synonyms | D6S204,HLA-C,HLA-JY3,HLAC,HLC-C,MHC,PSORS1 |
Uniprot Accession | P10321 |
Uniprot Entry Name | HLAC_HUMAN |
Protein Sub-location | Transmembrane Protein |
Category | |
Disease | Cancer |
Gene Ensembl | ENSG00000204525 |
Target Classification | Tumor-associated antigen (TAA) |
The target: HLA-C, gene name: HLA-C, also named as D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1. HLA-C belongs to the HLA class I heavy chain paralogues. This class I molecule is a heterodimer consisting of a heavy chain and a light chain (beta-2 microglobulin). The heavy chain is anchored in the membrane. Class I molecules play a central role in the immune system by presenting peptides derived from endoplasmic reticulum lumen. They are expressed in nearly all cells. The heavy chain is approximately 45 kDa and its gene contains 8 exons. Exon one encodes the leader peptide, exons 2 and 3 encode the alpha1 and alpha2 domain, which both bind the peptide, exon 4 encodes the alpha3 domain, exon 5 encodes the transmembrane region, and exons 6 and 7 encode the cytoplasmic tail. Polymorphisms within exon 2 and exon 3 are responsible for the peptide binding specificity of each class one molecule. Typing for these polymorphisms is routinely done for bone marrow and kidney transplantation. About 6000 HLA-C alleles have been described. The HLA system plays an important role in the occurrence and outcome of infectious diseases, including those caused by the malaria parasite, the human immunodeficiency virus (HIV), and the severe acute respiratory syndrome coronavirus (SARS-CoV). The structural spike and the nucleocapsid proteins of the novel coronavirus SARS-CoV-2, which causes coronavirus disease 2019 (COVID-19), are reported to contain multiple Class I epitopes with predicted HLA restrictions. Individual HLA genetic variation may help explain different immune responses to a virus across a population.[provided by RefSeq, Aug 2020].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.